Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
- 37 Downloads
KeywordsDiabetes mellitus Fulminant diabetes Glucose variability Coefficient of variation for glucose Labile diabetes Flash glucose monitoring FreeStyle Libre Autoimmune diabetes Immune checkpoint inhibitors side effects Immunotherapy Programmed cell death-1 Anti-PD-1 Programmed death ligand 1 Anti-PD-L1 Beta-cell pancreatic function Alpha-cell pancreatic function Exocrine pancreatic function
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.
Human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from all patients for being included in the study.
- 3.Marchand L, Reffet S, Vouillarmet J, Cugnet-Anceau C, Disse E, Thivolet C (2018) The 36% coefficient of variation for glucose proposed for separating stable and labile diabetes is clinically relevant: a continuous glucose monitoring-based study in a large population of type 1 diabetes patients. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.05.009 (PubMed PMID: 29910090) CrossRefPubMedGoogle Scholar